Genethon
Rome, Lazio, Italy · Biotechnology, Genetics, Health Care
Généthon is a pioneer in the discovery and development of gene therapies for rare diseases, established by the AFM-Téléthon. The organization employs over 200 scientists and professionals dedicated to developing innovative therapies that improve the lives of patients with rare genetic diseases. It is known for its contributions to the field, including the first gene therapy for spinal muscular atr
Key facts
- Headquarters
- Rome, Lazio, Italy
- Employees
- 302
- Industries
- Biotechnology, Genetics, Health Care
- Website
- www.genethon.com
- Company page
Recent activity at Genethon
- : Genethon Enters Licensing Agreement with AskBio to Develop Gene Therapy for Pompe Disease.
- : Genethon and Hansa Biopharma Launch Trial for Gene Therapy and Antibody Cleaving Enzyme Therapy Combination Treatment
- : Genethon Announces Latest Advances in Gene Therapies for Various Diseases at ESGCT 31st Annual Congress in Rome, Italy.
Leadership
- Iris Noel, Assistante Rh
- Sabine D., Genethon
- Gérald Perret, Global Programs Director
- Frederic Revah, Employee At Genethon
- Abbass J., Scientist and Pharmacist Specialized In Biotherapies
- Joëlle Cheuzeville, Usp Development Engineer
- Céline Contet, Experience In Communication and Events
- Angela Columbano, Not Specified
Verified email and direct lines for Genethon’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Genethon in the news
- Genethon’s Recent Accomplishments Underscore the Progress of Genetic Medicine from Scientific Promise to Clinical Reality - Business Wire (Jul 13, 2026)
- Genethon’s Gene Therapy GNT0004 Continues to Show Potential in DMD - CGTLive® (Mar 20, 2025)
- AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial - NeurologyLive (Jan 22, 2026)
- UPDATE: Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events - Fierce Biotech (May 17, 2022)
- Duchenne Muscular Dystrophy: Start of the pivotal phase of Genethon's gene therapy trial - AFM Téléthon (Jul 29, 2025)
- Gene Therapy GNT0004 Demonstrates Early Efficacy, Safety in Duchenne Muscular Dystrophy - NeurologyLive (Jun 12, 2024)
- Progress in Treating Patients Immunised Against AAV Vectors Used in Gene Therapy - AFM Téléthon (Oct 10, 2025)
- Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV - Business Wire (Oct 10, 2025)
Companies similar to Genethon
- Sangamo Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- Rocket Pharmaceuticals · Biotechnology, Genetics, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- uniQure · Biotechnology, Genetics, Health Care, Therapeutics
- Prime Medicine · Biotechnology, Genetics, Health Care, Therapeutics
About Genethon: questions and answers
What does Genethon do?
Généthon is a pioneer in the discovery and development of gene therapies for rare diseases, established by the AFM-Téléthon. The organization employs over 200 scientists and professionals dedicated to developing innovative therapies that improve the lives of patients with rare genetic diseases. It is known for its contributions to the field, including the first gene therapy for spinal muscular atr
Where is Genethon headquartered?
Genethon is headquartered in Rome, Lazio, Italy.
How many employees does Genethon have?
Genethon has about 302 employees.
What is the latest news on Genethon?
On Jan 14, 2026, Genethon Enters Licensing Agreement with AskBio to Develop Gene Therapy for Pompe Disease.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy